Founded in 1998 by a successful gentleman who was already well established in the biotechnology ball game, Seattle Genetics has a lot to thank from Dr. Clay Siegall, PhD.
After receiving his PhD from George Washington University in Philosophy, Dr. Siegall quickly started his road to success in the search for a cure in the fight against different forms of cancer. After working with the Nation Cancer Institute, National Institutes of Health, and Bristol-Meyers Squibb Pharmaceutical Research Institute, Dr. Siegall started Seattle Genetics.
Seattle Genetics is known for a multitude of antibody technologies, it is largely known for its antibody-drug conjugate (ADC) platform. This specific ADC, named ADCETRIS® (brentuximab vedotin), was approved in August of 2011 and helps in the fight of relapse in both Hodgkin lymphoma (HL) and mature T-cell lymphoma patients. But the road does not stop there. Seattle Genetics also has ADC programs for acute myeloid lymphoma and non-Hodgkin lymphoma; SGN-CD33A and SGN-CD19A respectively. Further, Seattle Genetics is reaching out to outside pharmaceutical and biotechnology companies for collaborations in both proprietary and collaborative programs that involves more than 20 ADC’s in clinical development.
One must say the future looks bright.
Being the company’s (Seattle Genetics) President, Chief Executive Officer, and a Board of Directors member, Dr. Siegall has brought in a whopping $675 million through public and private financing to aide in the hopes of finding a cure for different types of cancer. Making Seattle Genetics open to the public in 2001, the stock has been on a constant rise. You may agree he knows what he is doing. After all, he also serves on the Board of Directors for Alder BioPharmaceuticals and Mirna Therapeutics. With an accolade this strong, maybe there is a cure after all.